Cellular stress response in Eca-109 cells inhibits apoptosis during early exposure to isorhamnetin

Neoplasma

Volumn 59, Issue 4, 2012, Pages 361-369

  Shi, C ^a   Fan, L Y ^a   Cai, Z ^a   Liu, Y Y ^a   Yang, C L ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Cellular stress response; COX 2; Eca 109; Isorhamnetin; NF B

Indexed keywords

CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF DIFFERENTIATION 1; ISORHAMNETIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN MCL 1; PROTEIN P53; TRANSCRIPTION FACTOR RELA; 3-METHYLQUERCETIN; DRUG DERIVATIVE; PTGS2 PROTEIN, HUMAN; QUERCETIN; QUERCETIN 3 METHYL ETHER;

APOPTOSIS; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CELLULAR STRESS RESPONSE; CHEMOLUMINESCENCE; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UPREGULATION; WESTERN BLOTTING; CELL NUCLEUS; DRUG EFFECT; ESOPHAGUS TUMOR; GENE EXPRESSION; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SQUAMOUS CELL CARCINOMA; TUMOR CELL CULTURE;

APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL NUCLEUS; CELL PROLIFERATION; CYCLOOXYGENASE 2; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION; HUMANS; NF-KAPPA B; PHOSPHORYLATION; QUERCETIN; TUMOR CELLS, CULTURED;

EID: 84864559485     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2012_047     Document Type: Article

References (50)

1. PISANI P, BRAY F, PARKIN DM Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 2002; 97: 72-81. http://dx.doi.org/10.1002/ijc.1571
2. SOUZA RF Molecular and biologic basis of upper gastrointestinal malignancy-esophageal carcinoma. Surg Oncol Clin N Am 2002; 11: 257-272. http://dx.doi.org/10.1016/S1055-3207(02)00003-0
3. STONER GD, GUPTA A Etiology and chemoprevention of esophageal squamous cell carcinoma. Carcinogenesis 2001; 22: 1737-1746. http://dx.doi.org/10.1093/carcin/22.11.1737
4. ECHEVERRY C, BLASINA F, ARREDONDO F, FERREIRA M, ABIN-CARRIQUIRY JA et al. Cytoprotection by neutral fraction of tannat red wine against oxidative stress-induced cell death. J Agric Food Chem 2004; 52: 7395-7399. http://dx.doi.org/10.1021/jf040053q
5. IBARRA M, PEREZ-VIZCAINO F, COGOLLUDO A, DUARTE J, ZARAGOZA-ARNAEZ F et al. Cardiovascular effects of isorhamnetin and quercetin in isolated rat and porcine vascular smooth muscle and isolated rat atria. Planta Med 2002; 68: 307-310. http://dx.doi.org/10.1055/s-2002-26752
6. TENG BS, LU YH, WANG ZT, TAO XY, WEI DZ In vitro anti-tumor activity of isorhamnetin isolated from Hippophae rhamnoides L. against BEL-7402 cells. Pharmacol Res 2006; 54: 186-194. http://dx.doi.org/10.1016/j.phrs.2006.04.007
7. MA G, YANG CL, QU Y, WEI HY, ZHANG TT et al. The flavonoid component isorhamnetin in vitro inhibits and induces apoptosis in Eca-109 cells. Chem Biol Interact 2007; 167: 153-160. http://dx.doi.org/10.1016/j.cbi.2007.02.006
8. COURTOIS G, GILMORE TD Mutations in the NF-kappaB signaling pathway: implications for human disease. Oncogene 2006; 25: 6831-6843. http://dx.doi.org/10.1038/sj.onc.1209939
9. HAYDEN MS, GHOSH S Shared principles in NF-κB signaling. Cell 2008; 132: 344-362. http://dx.doi.org/10.1016/j.cell.2008.01.020
10. NEERGHEEN VS, BAHORUN T, TAYLOR EW, JEN LS, ARUOMA OI Targeting specific cell signaling transduction pathways by dietary and medicinal phytochemicals in cancer chemoprevention. Toxicol 2010; 278: 229-241. http://dx.doi.org/10.1016/j.tox.2009.10.010
11. XU Z, LIN S, WU W, TAN H, WANG Z et al. Ghrelin prevents doxorubicin-induced cardiotoxicity through TNF-alpha/NFkappaB pathways and mitochondrial protective mechanisms. Toxicol 2008; 247: 133-138. http://dx.doi.org/10.1016/j.tox.2008.02.018
12. LING MT, WANG X, OUYANG XS, XU K, TSAO SW et al. Id-1 expression promotes cell survival through activation of NF-kappaB signalling pathway in prostate cancer cells. Oncogene 2003; 22: 4498-4508. http://dx.doi.org/10.1038/sj.onc.1206693
13. KANE LP, SHAPIRO VS, STOKOE D, WEISS A Induction of NF-kappaB by the Akt/PKB kinase. Curr Biol 1999; 9: 601-604. http://dx.doi.org/10.1016/S0960-9822(99)80265-6
14. SMITH WL, GARAVITO RM, DEWITT DL Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and-2. J Biol Chem 1996; 271: 33157-33160. http://dx.doi.org/10.1074/jbc.271.17.9906
15. SMITH WL, DEWITT DL Biochemistry of prostaglandin endoperoxide H synthase-1 and synthase-2 and their differential susceptibility to nonsteroidal anti-inflammatory drugs. Semin Nephrol 1995; 15: 179-194.
16. HEMPEL SL, MONICK MM, HUNNINGHAKE GW Lipopolysaccharide induces prostaglandin H synthase-2 protein and mRNA in human alveolar macrophages and blood monocytes. J Clin Invest 1994; 93: 391-396. http://dx.doi.org/10.1172/JCI116971
17. COK SJ, MORRISON AR The 3'-untranslated region of murine cyclooxygenase-2 contains multiple regulatory elements that alter message stability and translational efficiency. J Biol Chem 2001; 276: 23179-23185. http://dx.doi.org/10.1074/jbc.M008461200
18. Li F, Liu Y, Chen H, Liao D, Shen Y et al. EGFR and COX-2 protein expression in non-small cell lung cancer and the correlation with clinical features. J Exp Clin Cancer Res 2011; 30(1): 32. http://dx.doi.org/10.1186/1756-9966-30-32
19. EL-SAYED M, TAHA MM Immunohistochemical expression of cycloxygenase-2 in astrocytoma: correlation with angiogenesis, tumor progression and survival. Turk Neurosurg 2011; 21: 27-35.
20. CHANDRASEKHARAN NV, DAI H, ROOS KL, EVANSON NK, TOMSIK J et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc. Natl. Acad. Sci. USA 2002; 99: 13926-13931. http://dx.doi.org/10.1073/pnas.162468699
21. DANNENBERG AJ, ALTORKI NK, BOYLE JO, DANG C, HOWE LR et al. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2001; 2: 544-551. http://dx.doi.org/10.1016/S1470-2045(01)00488-0
22. CHEN CC, SUN YT, CHEN JJ, CHANG YJ Tumor necrosis factor-induced cyclooxygenase-2 expression via sequential activation of ceramide-dependent mitogen-activated protein kinases, and IB kinase 1/2 in human alveolar epithelial cells. Mol Pharmacol 2001; 59: 493-500.
23. DEMPKE W, RIE C, GROTHEY A, SCHMOLL HJ Cyclooxygenase-2: a novel target for cancer chemotherapy. J Cancer Res Clin Oncol 2001; 127: 411-417. http://dx.doi.org/10.1007/s004320000225
24. PEPPELENBOSCH MP, TERTOOLEN LG, HAGE WJ, DE LAAT SW Epidermal growth factor-induced actin remodeling is regulated by 5-lipoxygenase and cyclooxygenase products. Cell 1993; 74: 565-575. http://dx.doi.org/10.1016/0092-8674(93)80057-L
25. ZHANG F, SUBBARAMAIAH K, ALTORKI N, DANNENBERG AJ Dihydroxy bile acids activate the transcription of cyclooxygenase-2. J Biol Chem 1998; 273: 2424-2428. http://dx.doi.org/10.1074/jbc.273.4.2424
26. SUBBARAMAIAH K, ALTORKI N, CHUNG WJ, MESTRE JR, SAMPAT A et al. Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem 1999; 274: 10911-10915. http://dx.doi.org/10.1074/jbc.274.16.10911
27. SHAO J, SHENG H, INOUE H, MORROW JD, DUBOIS RN Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells. J Biol Chem 2000; 275: 33951-33956. http://dx.doi.org/10.1074/jbc.M002324200
28. TANG Q, GONZALES M, INOUE H, BOWDEN GT Roles of Akt and glycogen synthase kinase 3β in the ultraviolet B induction of cyclooxygenase-2 transcription in human keratinocytes. Cancer Res 2001; 61: 4329-4332.
29. JONES DJ, LAMB JH, VERSCHOYLE RD, HOWELLS LM, BUTTERWORTH M et al. Characterisation of metabolites of the putative cancer chemopreventive agent quercetin and their effect on cyclooxygenase activity. Br J Cancer 2004; 91: 1213-1219.
30. HIDA T, YATABE Y, ACHIWA H, MURAMATSU H, KOZAKI K et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res1998; 58: 3761-3764.
31. RISTIMAKI A, HONKANEN N, JANKALA H, SIPPONEN P, HARKONEN M Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997; 57: 1276-1280.
32. SANO H, KAWAHITO Y, WILDER RL, HASHIRAMOTO A, MUKAI S et al. Expression of cyclooxygenase-1 and-2 in human colorectal cancer. Cancer Res 1995; 55: 3785-3789.
33. ZIMMERMANN KC, SARBIA M, WEBER AA, BORCHARD F, GABBERT HE et al. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999; 59: 198-204.
34. ZHI H, WANG L, ZHANG J, ZHOU C, DING F et al. Significance of COX-2 expression in human esophageal squamous cell carcinoma. Carcinogenesis 2006; 27: 1214-1221. http://dx.doi.org/10.1093/carcin/bgi304
35. BARNES PJ, KARIN M Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066-1071. http://dx.doi.org/10.1056/NEJM199704103361506
36. THIEL A, HEINONEN M, RINTAHAKA J, HALLIKAINEN T, HEMMES A et al. Expression of cyclooxygenase-2 is regulated by glycogen synthase kinase-3β in gastric cancer cells. J Biol Chem 2006; 281: 4564-4569. http://dx.doi.org/10.1074/jbc.M512722200
37. RODRIGUES S, BRUYNEEL E, RODRIGUE CM, SHAHIN E, GESPACH C Cyclooxygenase 2 and carcinogenesis. Bull Cancer 2004; 91: S61-76. [In French]
38. BALDWIN AS Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 2001; 107: 241-246. http://dx.doi.org/10.1172/JCI11991
39. PANDEY MK, SUNG B, AHN KS, KUNNUMAKKARA AB, CHATURVEDI MM et al. Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-kappaB signaling pathway. Blood 2007; 110: 3517-3525. http://dx.doi.org/10.1182/blood-2007-03-079616
40. DUBOIS RN, ABRAMSON SB, CROFFORD L, GUPTA RA, SIMON LS et al. Cyclooxygenase in biology and disease. FASEB J 1998; 12: 1063-1073.
41. LIU CH, CHANG SH, NARKO K, TRIFAN OC, WU MT et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001; 276: 18563-18569. http://dx.doi.org/10.1074/jbc.M010787200
42. TSUJII M, KAWANO S, TSUJI S, SAWAOKA H, HORI M et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705-716. http://dx.doi.org/10.1016/S0092-8674(00)81433-6
43. MULLER-DECKER K, NEUFANG G, BERGER I, NEUMANN M, MARKS F et al. Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. Proc Natl Acad Sci USA 2002; 99: 12483-12488. http://dx.doi.org/10.1073/pnas.192323799
44. WANG Y, CHANG J, LI YC, LI YS, SHYY JY et al. Shear stress and VEGF activate IKK via the Flk-1/Cbl/Akt signaling pathway. Am J Physiol Heart Circ Physiol 2004; 286: 685-692. http://dx.doi.org/10.1152/ajpheart.00237.2003
45. ST-GERMAIN ME, GAGNON V, MATHIEU I, PARENT S, ASSELIN E et al. Akt regulates COX-2 mRNA and protein expression in mutated-PTEN human endometrial cancer cells. Int J Oncol 2004; 24: 1311-1324.
46. HARA E, YAMAGUCHI T, NOJIMA H, IDE T, CAMPISI J et al. Id-related genes encoding helix-loop-helix proteins are required for G1 progression and are repressed in senescent human fibroblasts. J Biol Chem 1994; 269: 2139-2145.
47. HARA E, UZMAN JA, DIMRI GP, NEHLIN JO, TESTORI A et al. The helix-loop-helix protein Id-1 and a retinoblastoma protein binding mutant of SV40 T antigen synergize to reactivate DNA synthesis in senescent human fibroblasts. Dev Genet 1996; 18: 161-172. http://dx.doi.org/10.1002/(SICI)1520-6408(1996)18:2<161::AID-DVG9>3.0.CO;2-7
48. HO CC, LING YC, CHANG LW, TSAI HT, TSAI MH et al.17-beta estradiol and hydroxyestradiols interact via the NFKappaB pathway to elevate cyclooxygenase 2 expression and prostaglandin E2 secretion in human bronchial epithelial cells. Toxicol Sci 2008; 104: 294-302. http://dx.doi.org/10.1093/toxsci/kfn096
49. BREN-MATTISON Y, MEYER AM, VANPUTTEN V, LI H, KUHN K et al. Antitumorigenic effects of peroxisome proliferator-activated receptor in non-small-cell lung cancer cells are mediated by suppression of cyclooxygenase-2 via inhibition of nuclear factor. Mol Pharmacol 2008; 73: 709-717. http://dx.doi.org/10.1124/mol.107.042002
50. NZEAKO UC, GUICCIARDI ME, YOON JH, BRONK SF, GORES GJ COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells. Hepatol 2002; 35: 552-559. http://dx.doi.org/10.1053/jhep.2002.31774